Ironwood Pharmaceuticals (IRWD) Scheduled to Post Quarterly Earnings on Tuesday
Ironwood Pharmaceuticals (NASDAQ:IRWD) will issue its Q413 quarterly earnings data on Tuesday, January 21st. Investors that are interested in registering for the company’s conference call can do so using this link.
Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 12.66 on Monday. Ironwood Pharmaceuticals has a 1-year low of $8.95 and a 1-year high of $19.67. The stock’s 50-day moving average is $11.67 and its 200-day moving average is $11.31. The company’s market cap is $1.529 billion.
A number of analysts have recently weighed in on IRWD shares. Analysts at Zacks reiterated an “outperform” rating on shares of Ironwood Pharmaceuticals in a research note to investors on Wednesday, January 15th. They now have a $15.00 price target on the stock. On a related note, analysts at BMO Capital Markets upgraded shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note to investors on Friday, January 10th. Finally, analysts at Jefferies Group cut their price target on shares of Ironwood Pharmaceuticals from $12.00 to $11.00 in a research note to investors on Thursday, October 24th. They now have a “hold” rating on the stock. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the stock. Ironwood Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $13.39.
In other Ironwood Pharmaceuticals news, Director Bryan Roberts sold 21,200 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $12.57, for a total value of $266,484.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.